Pharvaris To Present Deucrictibant Clinical Data At The CIIC Spring 2024 Conference

(MENAFN- GlobeNewsWire - Nasdaq) ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX.

Presentation details:

  • Title: Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks
    Format: Digital Abstract Display Board
    Date, time: Saturday, April 13, 11:00-11:20 a.m. CDT (12:00-12:20 p.m. EDT)
  • Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
    Presenter: John Anderson, M.D.
    Format: E-Poster Presentation
    Date, time: Saturday, April 13, 11:20 a.m.-12:00 p.m. CDT (12:20-1:00 p.m. EDT)

The posters and associated presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentation sessions at: .

About Pharvaris
Building on its deep-seated roots in HAE, Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit .

CONTACT: ContactMaggie BellerExecutive Director, Head of External and Internal Communications...


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.